Phipps MM, Barraza LH, LaSota ED, et al. - In a retrospective cohort study conducted in the United States, researchers intended to distinguish the prevalence of and risk factors for the development of COVID‐19‐associated ALI. They evaluated all patients who had undergone SARS‐CoV‐2 testing at three hospitals in the NewYork‐Presbyterian network. Among 3,381 individuals, 2,273 tested positive; they also had higher initial and peak alanine aminotransferase than those who tested negative. Among patients who tested positive, 45% had mild, 21% moderate, and 6.4% severe liver injury (SLI). Severe ALI was significantly associated with elevated inflammatory markers, including ferritin and interleukin‐6, as seen in multivariable analysis. For SARS‐CoV‐2, ALI is common in patients who test positive but is most often mild. Nevertheless, a severe disease course should be anticipated among the 6.4% of patients with severe liver injury.